About Prof. Wang Zhuoying
Prof. Wang Zhuoying (王卓颏) is a Chief Physician (主任医师) and Director of the Department of Head and Neck Surgery at Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. He currently serves as Chairman of the Thyroid Committee of the Chinese Society of Clinical Oncology (CSCO) — the most senior national leadership position in thyroid oncology in China — and has participated in the drafting and interpretation of multiple authoritative national guidelines, including the Guidelines for the Diagnosis and Treatment of Differentiated Thyroid Cancer and the CSCO Guidelines for Medullary Thyroid Carcinoma.
Prof. Wang is one of China's foremost experts in advanced and locally advanced differentiated thyroid cancer, and is among the first specialists in China to lead clinical research on neoadjuvant targeted therapy for this indication — a pioneering approach that uses targeted drugs to shrink tumors before surgery, potentially converting previously inoperable cases into resectable ones and improving long-term outcomes. This research leadership, combined with his CSCO chairmanship and guideline authorship, places Prof. Wang at the absolute frontier of thyroid oncology in China.
Clinical Expertise
- Advanced differentiated thyroid cancer — comprehensive management of locally advanced and metastatic papillary and follicular thyroid carcinoma, including cases with tracheal, esophageal, vascular, or mediastinal involvement
- Neoadjuvant targeted therapy for thyroid cancer — clinical research pioneer in using targeted agents (lenvatinib, sorafenib, cabozantinib) before surgery to downstage advanced tumors and improve resectability; individualized treatment sequencing for complex cases
- RAI-refractory differentiated thyroid cancer — management of patients who have failed radioactive iodine therapy; targeted therapy selection, sequencing, and toxicity management; redifferentiation strategies to restore RAI sensitivity
- Medullary thyroid carcinoma (MTC) — guideline-level expertise in MTC diagnosis, RET mutation testing, surgical management, and systemic therapy with RET inhibitors (selpercatinib, pralsetinib, vandetanib, cabozantinib)
- Thyroid cancer surgery — total thyroidectomy, hemithyroidectomy, and neck dissection for all thyroid cancer subtypes; complex re-operative thyroid surgery
- Salivary gland tumors — diagnosis and surgical management of parotid, submandibular, and minor salivary gland tumors
- Soft tissue tumors of the head and neck — surgical management of cervical soft tissue sarcomas and other rare head and neck tumors
- Laryngeal tumors — surgical management within the comprehensive head and neck oncology framework
- Guideline-based individualized treatment planning — as CSCO Thyroid Committee Chairman, Prof. Wang provides treatment plans that are directly aligned with the most current national and international evidence
Why Prof. Wang Zhuoying?
For patients with advanced, recurrent, or RAI-refractory differentiated thyroid cancer — or with medullary thyroid carcinoma — Prof. Wang represents the highest level of specialist expertise available in China. His CSCO Thyroid Committee chairmanship is not an honorary title; it reflects active leadership in shaping how thyroid cancer is diagnosed and treated across China, and direct participation in the guideline development process that determines standard of care for millions of patients.
His pioneering work in neoadjuvant targeted therapy is particularly significant for international patients who have been told that their advanced thyroid cancer is inoperable. The concept of using targeted drugs to shrink a tumor before surgery — well-established in breast cancer and other malignancies — is being actively explored in thyroid cancer, and Prof. Wang is one of the few specialists in China with hands-on clinical research experience in this approach. For patients who have exhausted standard options or who face a technically challenging resection, access to this expertise can be genuinely transformative.
His guideline authorship also means that international patients who consult Prof. Wang receive treatment recommendations that are not just based on his personal experience but are grounded in the same evidence base that informs national treatment standards — providing a level of confidence and transparency that is particularly valuable for patients navigating complex oncological decisions from abroad.
Hospital: Renji Hospital, Shanghai Jiao Tong University School of Medicine
Renji Hospital is one of Shanghai's most prestigious academic medical centers, with a history spanning over 160 years. Its Department of Head and Neck Surgery — directed by Prof. Wang — is a comprehensive program with advanced surgical infrastructure, intraoperative nerve monitoring, and a multidisciplinary tumor board integrating head and neck surgery, medical oncology, nuclear medicine, radiation oncology, and pathology. The hospital's active clinical trials program provides access to investigational agents for patients with advanced thyroid cancer who have exhausted standard options.
About Advanced & RAI-Refractory Thyroid Cancer
While most thyroid cancers are highly treatable, a subset of patients develop advanced or treatment-resistant disease that requires specialist expertise. Key facts for international patients:
- RAI-refractory differentiated thyroid cancer: defined as disease that no longer concentrates radioactive iodine or progresses despite RAI therapy; affects approximately 5–15% of patients with metastatic differentiated thyroid cancer; 10-year survival drops to ~10% without effective systemic therapy
- Targeted therapy options: lenvatinib (first-line, ~65% response rate) and sorafenib (first-line, ~12% response rate) are approved; cabozantinib is approved as second-line; selpercatinib for RET-mutated disease
- Redifferentiation: MEK inhibitors (trametinib) and BRAF inhibitors (dabrafenib) can restore RAI sensitivity in BRAF V600E-mutated tumors, enabling additional RAI therapy
- Neoadjuvant targeted therapy: use of targeted agents before surgery to downstage locally advanced tumors; emerging evidence supports this approach for selected patients with tracheal or vascular involvement
- Medullary thyroid carcinoma (MTC): 25% are hereditary (RET germline mutation); all patients should undergo RET testing; selpercatinib achieves ~69% response rate in RET-mutated MTC; calcitonin and CEA are tumor markers for monitoring
- Anaplastic thyroid cancer (ATC): BRAF V600E present in ~45%; dabrafenib + trametinib achieves ~56% response rate in BRAF-mutated ATC; immunotherapy combinations under investigation
What to Prepare Before Your Consultation
To enable Prof. Wang's team to conduct a thorough remote case review, international patients should prepare:
- CT scan of the neck, chest, and abdomen with contrast (for staging and assessment of local invasion and distant metastases)
- PET-CT if available (for RAI-refractory disease assessment)
- Most recent RAI scan results and cumulative RAI dose history
- Pathology report with molecular testing: BRAF V600E, RET, RAS mutations; TERT promoter mutation status
- Thyroid function tests: TSH, free T4
- Tumor markers: thyroglobulin (Tg) and anti-Tg antibodies; calcitonin and CEA for medullary thyroid cancer
- Complete prior treatment history: surgery dates and extent, RAI doses and responses, targeted therapy history with best response and reason for discontinuation
- Laryngoscopy report if voice changes are present
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Prof. Wang Zhuoying and the Renji Hospital Head and Neck Surgery team for international patients with advanced thyroid cancer. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Prof. Wang's team at Renji Hospital
- Full translation of imaging reports, pathology, molecular testing results, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개